Wuhan, China and Redwood City, California, USA, Sept. 08, 2021 (GLOBE NEWSWIRE) - Kerry Corning announced today that it will administer XW10508 to subjects in the first human trial to study and evaluate XW10508. It is a two-way regulator of NMDA receptor antagonist and AMPA receptor activation independently developed by the company and has global intellectual property protection; it is being developed as an oral, once-a-day therapy for the treatment of refractory depression and chronic pain .
REDWOOD CITY, Calif. and WUHAN, China, June 14, 2021 (GLOBE NEWSWIRE) -- XWPharma Ltd. today announced that XW10172, an internally discovered, novel, patented conjugate of the GABAB agonist oxybate, demonstrated in Phase 1 clinical trials multiple features that support development for treatment for various sleep disorders. The results of these studies were presented by Daniel Canafax, PharmD, Chief Medical Officer of the company, in a podium presentation at virtual SLEEP 2021, the annual meeting of the Associated Professional Sleep Societies.